Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Senzime AB ( (SE:SEZI) ) just unveiled an announcement.
Senzime AB has secured a significant order from a leading NHS hospital trust in the UK for 70 TetraGraph systems, marking its largest European order to date. This strategic win aligns with UK guidelines mandating quantitative monitoring in operating theaters, positioning Senzime for broader expansion and reinforcing its commitment to enhancing patient safety through advanced neuromuscular monitoring technology.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph system, is renowned for its accurate monitoring of neuromuscular transmission during surgery, aiding in precise dosing of paralytic drugs. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 395,773
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK749.9M
See more insights into SEZI stock on TipRanks’ Stock Analysis page.